Article | August 10, 2021

Benefits Of RABS And Isolator Technology In A Changing Regulatory Landscape

By Ryan Rivers, Shane Mohr, and Lisa DeOerio, Emergent BioSolutions

iStock-941351188-lab-cleanroom-sterile

Mitigating risk is a key consideration for pharmaceutical companies when planning their clinical trial material and/or drug product manufacturing processes. One of the most prevalent sources is material handling: every step in the drug substance or drug product manufacturing process can introduce risk. Biopharmaceutical companies and contract development and manufacturing organizations (CDMOs) collaborate to ensure a number of technologies are utilized to safeguard the integrity of these products. One method is to leverage a Restricted Access Barrier System (RABS) or isolator technology during drug product manufacturing.

This equipment represents an integral component of a manufacturer’s quality control strategy. The current regulatory landscape requires drug manufacturers to employ a RABS or isolator as part of their risk mitigation approach, and each technology possesses pros and cons depending on the parameters and requirements of a project. While each one is robust enough to ensure consistent and reliable production, companies looking to develop in-house capabilities or contract to a CDMO should understand the key elements of both in order to make the best, most informed decision for their product.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: